Brinton Pharmaceuticals has recently forayed into the paediatric segment. Rahul Darda, CMD, Brinton Pharmaceuticals reveals more about the new venture and their future plans in an interaction with Usha Sharma
Brinton Pharma is looking out for acquisitions to expand its business. Give us a brief understanding on this plan.
Yes, Brinton is looking out for acquisitions and it would definitely help us to increase our market share, but things are at a very nascent stage.
You are considering for a buyout. How will this add value to your business?
Brinton has always believed in building brands and has a patient-centric approach. And that’s why acquiring a brand which are having a similar brand personality would be a good match for Brinton to go a long way in creating better healthcare. Finally, the objective is to gain more market share and buy some big brands in therapy areas, which will help us to establish ourselves.
Tell us more about your investment in the paediatric segment.
Brinton launched its paediatric division in the month of July 2017 with a field force of around 200 people. We are in the process of further expanding our paediatric business to have a more aggressive presence in the market. Within paediatric segment, we have products ranging from paediatric nutrition, respiratory and other therapy areas and they are already available in the market. Brinton is currently pursuing a strong R&D to bring more innovative products within paediatric nutrition, respiratory apart from dermatology-based products in psoriasis and vitiligo. Funds have been arranged internally to pursue this growth.
How many new products do you plan to launch from your Pune facility?
Our new R&D facility is equipped to offer products for psoriasis and vitiligo along with a range of products in paediatric nutrition and respiratory and neonatology. Few products are in the process of being launched in the market very soon.
Tell us about your international presence. Do you plan to venture into new markets?
Our products are currently available in African and South Asian countries. And Brinton in already having its presence in 12 international markets and in the process of launching its products in another 20 countries.
Which new therapeutic areas do you plan to venture?
In the coming years, the company plans to start operations in gynaecology, neurology and orthopaedics. All these three segments are growing at a rapid pace with an average CAGR of 10 per cent and above. The growth has been propelled by the presence of a large patient base for target diseases, rising awareness about the disease and increased healthcare expenditures.
How many products are in the pipeline and for which therapeutic areas are they?
Many products are in the pipeline. To name a few, we have products in the following segments:
With massive expansion in the pipeline, do you plan to increase the number of employees in your organisation?
At present, we have more than 600 people who are directly associated with Brinton Pharmaceuticals. The company has recently launched its paediatric field force with more than 200 people and there are plans to expand further. With Brinton’s expansion in the international markets, we are in the final stages of recruiting more manpower in these countries. Brinton is also creating indirect employment for more than 5000 people in manufacturing.
What are your corporate plans for the next 2-3 years?
Brinton plans for an aggressive growth to become Rs 500-crore company by 2021. We have already launched the paediatric division and plan to expand into gynaecology, orthopaedics and neurology. Brinton is already expanding operations in 20 more international markets of Asia, Africa and Latin America.The next phase of expansion will see the company growing in Europe and CIS markets.